{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 21f5cd1b-b7fc-441a-b832-d5d396594b07 --><h2>Changes</h2><!-- end field 21f5cd1b-b7fc-441a-b832-d5d396594b07 -->","summary":null,"htmlStringContent":"<!-- begin item b5116551-a9b9-4a87-bb39-885f3c279731 --><!-- begin field 20ff842d-533b-4263-9a27-a5a8f446ad72 --><p><strong>November 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>July 2020</strong> — reviewed. A literature search was conducted in July 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. No major changes to the recommendations have been made.</p><!-- end field 20ff842d-533b-4263-9a27-a5a8f446ad72 --><!-- end item b5116551-a9b9-4a87-bb39-885f3c279731 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"1267499d-1fb8-54d0-be4b-2b57393b2534","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f6ff64a1-278d-4a48-8af0-cab2934e6c09 --><h3>Previous changes</h3><!-- end field f6ff64a1-278d-4a48-8af0-cab2934e6c09 -->","summary":null,"htmlStringContent":"<!-- begin item b0ec3954-bf26-492d-a0f7-ce5133f5eb0d --><!-- begin field 9da54be0-855e-4526-b9af-05fd62e9d1cb --><p><strong>March 2020 </strong> — minor update. Possible side effects of abrupt discontinuation of pramipexole have been included, in line with changes to manufacturer SPC.<br><br><strong>December 2016</strong> — minor update. Peripheral oedema and dopamine dysregulation syndrome have been included as possible adverse effects of ropinirole, and information that ropinirole should not be used in secondary causes of restless legs syndrome has been added, in line with changes to the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2016</a>].</p><p><strong>October 2015 </strong>— minor update. Dopamine dysregulation syndrome has been included as a possible adverse effect of rotigotine (frequency is unknown) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI Medicines Compendium, 2015</a>].</p><p><strong>January to March 2015</strong> — reviewed. A literature search was conducted in January 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic.</p><p>Recommendations have been changed to be in line with the International Restless Legs Syndrome Study Group guideline <em>The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2013</a>] which recommends first-line drug treatment for people with moderate to severe symptoms to be either a non-ergot dopamine agonist (pramipexole, ropinirole, or rotigotine), or an alpha-2-delta ligand (pregabalin or gabapentin — both off-label indications).</p><p><strong>June 2014 </strong>— minor update. Update to the text to reflect the fact that tramadol has been reclassified to a schedule 3 controlled drug.</p><p><strong>July 2011 </strong>— minor update. The choice of drug treatment has been updated in line with evidence from a long-term study on the safety, efficacy and risk of augmentation with rotigotine transdermal patch. Issued in September 2011.</p><p><strong>August to December 2009 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 9da54be0-855e-4526-b9af-05fd62e9d1cb --><!-- end item b0ec3954-bf26-492d-a0f7-ce5133f5eb0d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}